25 XP   0   0   10

Yungjin Pharm Co Ltd
Buy, Hold or Sell?

Let's analyse Yungjin together

PenkeI guess you are interested in Yungjin Pharm Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Yungjin Pharm Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Yungjin Pharm Co Ltd

I send you an email if I find something interesting about Yungjin Pharm Co Ltd.

Quick analysis of Yungjin (30 sec.)










What can you expect buying and holding a share of Yungjin? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩490.08
Expected worth in 1 year
₩488.78
How sure are you?
42.9%

+ What do you gain per year?

Total Gains per Share
₩-1.30
Return On Investment
-0.1%

For what price can you sell your share?

Current Price per Share
₩2,100.00
Expected price per share
₩2,005 - ₩2,290
How sure are you?
50%

1. Valuation of Yungjin (5 min.)




Live pricePrice per Share (EOD)

₩2,100.00

Intrinsic Value Per Share

₩-3,853.32 - ₩-4,604.28

Total Value Per Share

₩-3,363.24 - ₩-4,114.20

2. Growth of Yungjin (5 min.)




Is Yungjin growing?

Current yearPrevious yearGrowGrow %
How rich?$62.7m$69.1m-$7m-11.3%

How much money is Yungjin making?

Current yearPrevious yearGrowGrow %
Making money-$678.2k-$3.8m$3.1m466.7%
Net Profit Margin-1.6%-9.5%--

How much money comes from the company's main activities?

3. Financial Health of Yungjin (5 min.)




What can you expect buying and holding a share of Yungjin? (5 min.)

Welcome investor! Yungjin's management wants to use your money to grow the business. In return you get a share of Yungjin.

What can you expect buying and holding a share of Yungjin?

First you should know what it really means to hold a share of Yungjin. And how you can make/lose money.

Speculation

The Price per Share of Yungjin is ₩2,100. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Yungjin.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Yungjin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩490.08. Based on the TTM, the Book Value Change Per Share is ₩-0.33 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-20.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Yungjin.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.000.0%0.000.0%-0.020.0%-0.010.0%0.000.0%
Usd Book Value Change Per Share0.010.0%0.000.0%-0.010.0%0.000.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.0%0.000.0%-0.010.0%0.000.0%0.010.0%
Usd Price Per Share1.49-1.72-2.57-3.38-4.18-
Price to Earnings Ratio-83.36--285.33--86.69--132.47--70.94-
Price-to-Total Gains Ratio169.00--2,119.99--350.66--616.04-651.65-
Price to Book Ratio4.34-5.06-6.78-8.15-9.79-
Price-to-Total Gains Ratio169.00--2,119.99--350.66--616.04-651.65-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.47
Number of shares680
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (680 shares)-0.15-3.32
Gains per Year (680 shares)-0.62-13.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1-110-13-23
20-1-120-27-36
30-2-130-40-49
40-2-140-53-62
50-3-150-66-75
60-4-160-80-88
70-4-170-93-101
80-5-180-106-114
90-6-190-119-127
100-6-200-133-140

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%5.015.00.025.0%9.019.00.032.1%9.019.00.032.1%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.016.00.042.9%12.016.00.042.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.028.00.0%0.00.028.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.016.00.042.9%12.016.00.042.9%

Fundamentals of Yungjin

About Yungjin Pharm Co Ltd

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs. Yungjin Pharm. Co., Ltd. was founded in 1952 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 20:43:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Yungjin Pharm Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Yungjin earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.8% means that ₩-0.02 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Yungjin Pharm Co Ltd:

  • The MRQ is -1.8%. The company is making a loss. -1
  • The TTM is -1.6%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-1.8%TTM-1.6%-0.2%
TTM-1.6%YOY-9.5%+7.8%
TTM-1.6%5Y-3.0%+1.4%
5Y-3.0%10Y-2.4%-0.6%
1.1.2. Return on Assets

Shows how efficient Yungjin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Assets means that Yungjin generated ₩-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Yungjin Pharm Co Ltd:

  • The MRQ is -0.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-0.4%-0.1%
TTM-0.4%YOY-2.7%+2.3%
TTM-0.4%5Y-0.8%+0.4%
5Y-0.8%10Y-0.6%-0.2%
1.1.3. Return on Equity

Shows how efficient Yungjin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.3% Return on Equity means Yungjin generated ₩-0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Yungjin Pharm Co Ltd:

  • The MRQ is -1.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.3%TTM-1.1%-0.2%
TTM-1.1%YOY-6.0%+4.9%
TTM-1.1%5Y-1.7%+0.6%
5Y-1.7%10Y-1.3%-0.4%

1.2. Operating Efficiency of Yungjin Pharm Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Yungjin is operating .

  • Measures how much profit Yungjin makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Yungjin Pharm Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y2.3%-2.3%
5Y2.3%10Y1.5%+0.9%
1.2.2. Operating Ratio

Measures how efficient Yungjin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.65 means that the operating costs are ₩1.65 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Yungjin Pharm Co Ltd:

  • The MRQ is 1.646. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.681. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.646TTM1.681-0.034
TTM1.681YOY1.736-0.056
TTM1.6815Y1.686-0.006
5Y1.68610Y1.680+0.007

1.3. Liquidity of Yungjin Pharm Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Yungjin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.69 means the company has ₩1.69 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Yungjin Pharm Co Ltd:

  • The MRQ is 1.686. The company is able to pay all its short-term debts. +1
  • The TTM is 1.960. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.686TTM1.960-0.274
TTM1.960YOY1.914+0.047
TTM1.9605Y2.480-0.520
5Y2.48010Y2.609-0.129
1.3.2. Quick Ratio

Measures if Yungjin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.74 means the company can pay off ₩0.74 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Yungjin Pharm Co Ltd:

  • The MRQ is 0.740. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.884. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.740TTM0.884-0.144
TTM0.884YOY0.932-0.049
TTM0.8845Y1.123-0.240
5Y1.12310Y1.249-0.126

1.4. Solvency of Yungjin Pharm Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Yungjin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Yungjin to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.60 means that Yungjin assets are financed with 60.4% credit (debt) and the remaining percentage (100% - 60.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Yungjin Pharm Co Ltd:

  • The MRQ is 0.604. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.589. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.604TTM0.589+0.016
TTM0.589YOY0.515+0.074
TTM0.5895Y0.474+0.114
5Y0.47410Y0.460+0.015
1.4.2. Debt to Equity Ratio

Measures if Yungjin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 152.8% means that company has ₩1.53 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Yungjin Pharm Co Ltd:

  • The MRQ is 1.528. The company is just able to pay all its debts with equity.
  • The TTM is 1.436. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.528TTM1.436+0.092
TTM1.436YOY1.066+0.370
TTM1.4365Y0.941+0.495
5Y0.94110Y0.882+0.059

2. Market Valuation of Yungjin Pharm Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Yungjin generates.

  • Above 15 is considered overpriced but always compare Yungjin to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -83.36 means the investor is paying ₩-83.36 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Yungjin Pharm Co Ltd:

  • The EOD is -82.377. Based on the earnings, the company is expensive. -2
  • The MRQ is -83.358. Based on the earnings, the company is expensive. -2
  • The TTM is -285.329. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-82.377MRQ-83.358+0.981
MRQ-83.358TTM-285.329+201.971
TTM-285.329YOY-86.695-198.634
TTM-285.3295Y-132.470-152.859
5Y-132.47010Y-70.939-61.530
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Yungjin Pharm Co Ltd:

  • The EOD is -12.633. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.783. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 15.047. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-12.633MRQ-12.783+0.150
MRQ-12.783TTM15.047-27.830
TTM15.047YOY-7.645+22.692
TTM15.0475Y60.134-45.087
5Y60.13410Y26.413+33.721
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Yungjin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.34 means the investor is paying ₩4.34 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Yungjin Pharm Co Ltd:

  • The EOD is 4.285. Based on the equity, the company is fair priced.
  • The MRQ is 4.336. Based on the equity, the company is fair priced.
  • The TTM is 5.061. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.285MRQ4.336-0.051
MRQ4.336TTM5.061-0.725
TTM5.061YOY6.781-1.721
TTM5.0615Y8.154-3.094
5Y8.15410Y9.791-1.637
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Yungjin Pharm Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--12.574-0.325+103%-20.525+263%-6.965+155%17.503-28%
Book Value Per Share--490.082485.180+1%540.177-9%578.127-15%595.574-18%
Current Ratio--1.6861.960-14%1.914-12%2.480-32%2.609-35%
Debt To Asset Ratio--0.6040.589+3%0.515+17%0.474+27%0.460+31%
Debt To Equity Ratio--1.5281.436+6%1.066+43%0.941+62%0.882+73%
Dividend Per Share----0%-0%-0%-0%
Eps---6.373-5.298-17%-30.019+371%-8.891+40%-6.932+9%
Free Cash Flow Per Share---41.559-27.969-33%-33.913-18%-11.238-73%-9.080-78%
Free Cash Flow To Equity Per Share---41.559-27.969-33%-33.913-18%-11.238-73%-11.286-73%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4604.278--------
Intrinsic Value_10Y_min---3853.319--------
Intrinsic Value_1Y_max---142.151--------
Intrinsic Value_1Y_min---139.440--------
Intrinsic Value_3Y_max---670.398--------
Intrinsic Value_3Y_min---635.105--------
Intrinsic Value_5Y_max---1491.960--------
Intrinsic Value_5Y_min---1363.859--------
Market Cap384073200000.000-1%388646464750.000449229590137.500-13%672358384017.500-42%881907451381.000-56%1093239649165.000-64%
Net Profit Margin---0.018-0.016-10%-0.095+423%-0.030+66%-0.024+34%
Operating Margin----0%-0%0.023-100%0.015-100%
Operating Ratio--1.6461.681-2%1.736-5%1.686-2%1.680-2%
Pb Ratio4.285-1%4.3365.061-14%6.781-36%8.154-47%9.791-56%
Pe Ratio-82.377+1%-83.358-285.329+242%-86.695+4%-132.470+59%-70.939-15%
Price Per Share2100.000-1%2125.0002456.250-13%3676.250-42%4822.000-56%5977.500-64%
Price To Free Cash Flow Ratio-12.633+1%-12.78315.047-185%-7.645-40%60.134-121%26.413-148%
Price To Total Gains Ratio167.010-1%168.998-2119.994+1354%-350.655+307%-616.037+465%651.647-74%
Quick Ratio--0.7400.884-16%0.932-21%1.123-34%1.249-41%
Return On Assets---0.005-0.004-13%-0.027+425%-0.008+60%-0.006+25%
Return On Equity---0.013-0.011-16%-0.060+358%-0.017+34%-0.013+3%
Total Gains Per Share--12.574-0.325+103%-20.525+263%-6.965+155%17.503-28%
Usd Book Value--62742640.90562115025.760+1%69156066.963-9%74014541.035-15%76248153.753-18%
Usd Book Value Change Per Share--0.0090.000+103%-0.014+263%-0.005+155%0.012-28%
Usd Book Value Per Share--0.3430.340+1%0.378-9%0.405-15%0.417-18%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.004-0.004-17%-0.021+371%-0.006+40%-0.005+9%
Usd Free Cash Flow---5320563.948-3580751.186-33%-4341723.750-18%-1438695.995-73%-1162415.890-78%
Usd Free Cash Flow Per Share---0.029-0.020-33%-0.024-18%-0.008-73%-0.006-78%
Usd Free Cash Flow To Equity Per Share---0.029-0.020-33%-0.024-18%-0.008-73%-0.008-73%
Usd Market Cap268851240.000-1%272052525.325314460713.096-13%470650868.812-42%617335215.967-56%765267754.416-64%
Usd Price Per Share1.470-1%1.4881.719-13%2.573-42%3.375-56%4.184-64%
Usd Profit---815914.533-678220.090-17%-3843181.897+371%-1138278.279+40%-887520.920+9%
Usd Revenue--45018383.19341107930.532+10%38216672.799+18%37741571.764+19%36353619.119+24%
Usd Total Gains Per Share--0.0090.000+103%-0.014+263%-0.005+155%0.012-28%
 EOD+2 -6MRQTTM+13 -19YOY+16 -165Y+16 -1710Y+12 -21

3.2. Fundamental Score

Let's check the fundamental score of Yungjin Pharm Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-82.377
Price to Book Ratio (EOD)Between0-14.285
Net Profit Margin (MRQ)Greater than0-0.018
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.740
Current Ratio (MRQ)Greater than11.686
Debt to Asset Ratio (MRQ)Less than10.604
Debt to Equity Ratio (MRQ)Less than11.528
Return on Equity (MRQ)Greater than0.15-0.013
Return on Assets (MRQ)Greater than0.05-0.005
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Yungjin Pharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.195
Ma 20Greater thanMa 502,064.250
Ma 50Greater thanMa 1002,060.400
Ma 100Greater thanMa 2002,063.550
OpenGreater thanClose2,060.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets226,600,824
Total Liabilities136,968,480
Total Stockholder Equity89,632,344
 As reported
Total Liabilities 136,968,480
Total Stockholder Equity+ 89,632,344
Total Assets = 226,600,824

Assets

Total Assets226,600,824
Total Current Assets126,564,018
Long-term Assets100,036,806
Total Current Assets
Cash And Cash Equivalents 7,207,712
Short-term Investments 3,000,000
Net Receivables 52,531,104
Inventory 61,986,611
Other Current Assets 0
Total Current Assets  (as reported)126,564,018
Total Current Assets  (calculated)124,725,427
+/- 1,838,591
Long-term Assets
Property Plant Equipment 85,318,625
Intangible Assets 2,315,028
Long-term Assets Other 0
Long-term Assets  (as reported)100,036,806
Long-term Assets  (calculated)87,633,653
+/- 12,403,153

Liabilities & Shareholders' Equity

Total Current Liabilities75,055,135
Long-term Liabilities61,913,345
Total Stockholder Equity89,632,344
Total Current Liabilities
Short Long Term Debt 25,000,000
Accounts payable 19,407,907
Other Current Liabilities 1,340,315
Total Current Liabilities  (as reported)75,055,135
Total Current Liabilities  (calculated)45,748,222
+/- 29,306,914
Long-term Liabilities
Long term Debt 40,377,807
Capital Lease Obligations Min Short Term Debt1,504,239
Long-term Liabilities Other 1,833,729
Long-term Liabilities  (as reported)61,913,345
Long-term Liabilities  (calculated)43,715,775
+/- 18,197,570
Total Stockholder Equity
Total Stockholder Equity (as reported)89,632,344
Total Stockholder Equity (calculated)0
+/- 89,632,344
Other
Capital Stock91,446,366
Common Stock Shares Outstanding 182,892
Net Debt 58,170,095
Net Invested Capital 155,010,151
Net Working Capital 51,508,883
Property Plant and Equipment Gross 164,840,263



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
199,354,385
207,413,990
210,675,633
205,971,819
203,846,089
199,597,020
195,859,292
198,551,981
201,858,413
210,617,577
196,972,305
200,445,669
202,768,716
202,280,592
200,390,214
188,100,730
192,120,997
190,181,803
185,040,168
194,095,213
203,168,233
203,961,079
203,872,459
203,082,817
207,388,682
210,485,550
219,984,779
226,600,824
226,600,824219,984,779210,485,550207,388,682203,082,817203,872,459203,961,079203,168,233194,095,213185,040,168190,181,803192,120,997188,100,730200,390,214202,280,592202,768,716200,445,669196,972,305210,617,577201,858,413198,551,981195,859,292199,597,020203,846,089205,971,819210,675,633207,413,990199,354,385
   > Total Current Assets 
101,564,859
103,270,530
105,357,063
116,682,209
114,018,976
111,435,749
107,298,864
108,363,664
113,259,178
120,740,761
108,486,873
111,330,071
114,523,180
113,529,936
109,937,585
98,674,577
102,141,277
96,076,119
90,802,061
89,687,991
99,588,380
102,152,431
101,258,593
102,194,443
105,556,210
109,514,444
119,346,048
126,564,018
126,564,018119,346,048109,514,444105,556,210102,194,443101,258,593102,152,43199,588,38089,687,99190,802,06196,076,119102,141,27798,674,577109,937,585113,529,936114,523,180111,330,071108,486,873120,740,761113,259,178108,363,664107,298,864111,435,749114,018,976116,682,209105,357,063103,270,530101,564,859
       Cash And Cash Equivalents 
1,669,606
3,231,225
7,632,274
2,528,859
4,185,003
5,089,563
1,752,269
1,166,660
1,347,663
1,484,538
1,422,337
651,873
666,763
1,114,768
588,752
427,687
380,341
533,806
1,481,043
464,571
347,085
826,153
234,297
682,254
275,223
1,397,829
1,501,998
7,207,712
7,207,7121,501,9981,397,829275,223682,254234,297826,153347,085464,5711,481,043533,806380,341427,687588,7521,114,768666,763651,8731,422,3371,484,5381,347,6631,166,6601,752,2695,089,5634,185,0032,528,8597,632,2743,231,2251,669,606
       Short-term Investments 
0
0
4,999,043
8,999,764
8,000,000
7,000,000
8,000,000
6,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,000,000
3,000,00000000000000000000006,000,0008,000,0007,000,0008,000,0008,999,7644,999,04300
       Net Receivables 
54,532,356
49,747,600
43,218,029
54,719,036
56,927,300
55,701,447
50,475,166
53,111,726
54,825,164
59,703,458
48,636,015
48,746,558
48,754,133
45,636,600
45,196,390
43,567,366
42,974,829
42,461,002
40,929,455
46,987,316
52,869,333
47,459,788
46,392,316
51,083,278
49,877,685
47,852,552
52,893,937
52,531,104
52,531,10452,893,93747,852,55249,877,68551,083,27846,392,31647,459,78852,869,33346,987,31640,929,45542,461,00242,974,82943,567,36645,196,39045,636,60048,754,13348,746,55848,636,01559,703,45854,825,16453,111,72650,475,16655,701,44756,927,30054,719,03643,218,02949,747,60054,532,356
       Inventory 
44,119,416
44,564,255
44,377,123
46,011,760
40,687,077
38,873,336
43,418,163
45,786,141
51,680,616
53,369,289
51,819,414
55,956,897
59,198,287
62,370,507
61,319,431
51,435,434
52,982,961
49,605,116
43,578,337
39,653,092
42,403,092
49,564,999
51,313,847
48,463,281
52,193,991
57,644,310
62,291,737
61,986,611
61,986,61162,291,73757,644,31052,193,99148,463,28151,313,84749,564,99942,403,09239,653,09243,578,33749,605,11652,982,96151,435,43461,319,43162,370,50759,198,28755,956,89751,819,41453,369,28951,680,61645,786,14143,418,16338,873,33640,687,07746,011,76044,377,12344,564,25544,119,416
       Other Current Assets 
959,018
4,509,279
4,943,358
4,301,237
3,877,060
4,644,522
3,498,472
2,050,868
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,050,8683,498,4724,644,5223,877,0604,301,2374,943,3584,509,279959,018
   > Long-term Assets 
0
0
0
0
0
0
0
0
88,599,234
89,876,817
88,485,432
89,115,599
88,245,536
88,750,655
90,452,629
89,426,153
89,979,719
94,105,684
94,238,107
104,407,222
103,579,853
101,808,648
102,613,866
100,888,374
101,832,472
100,971,106
100,638,731
100,036,806
100,036,806100,638,731100,971,106101,832,472100,888,374102,613,866101,808,648103,579,853104,407,22294,238,10794,105,68489,979,71989,426,15390,452,62988,750,65588,245,53689,115,59988,485,43289,876,81788,599,23400000000
       Property Plant Equipment 
68,032,915
68,584,030
69,675,061
71,902,639
72,576,820
71,557,092
71,304,983
71,159,322
0
0
0
0
0
0
0
0
0
0
0
0
0
0
85,833,899
85,639,525
84,906,244
84,507,238
85,026,643
85,318,625
85,318,62585,026,64384,507,23884,906,24485,639,52585,833,8990000000000000071,159,32271,304,98371,557,09272,576,82071,902,63969,675,06168,584,03068,032,915
       Long Term Investments 
10,447
10,447
10,447
10,447
10,447
10,357
10,357
10,357
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000010,35710,35710,35710,44710,44710,44710,44710,447
       Intangible Assets 
2,261,932
8,176,468
8,004,350
7,977,555
7,791,232
6,723,896
6,576,747
6,360,577
2,334,610
2,299,791
2,228,494
2,212,730
2,074,886
2,009,856
1,935,538
1,564,840
1,615,182
1,707,942
1,643,842
1,441,846
1,129,388
2,388,421
2,461,900
2,679,164
2,620,546
2,485,362
2,348,115
2,315,028
2,315,0282,348,1152,485,3622,620,5462,679,1642,461,9002,388,4211,129,3881,441,8461,643,8421,707,9421,615,1821,564,8401,935,5382,009,8562,074,8862,212,7302,228,4942,299,7912,334,6106,360,5776,576,7476,723,8967,791,2327,977,5558,004,3508,176,4682,261,932
       Long-term Assets Other 
0
0
0
0
0
0
0
0
1,454,401
1,274,810
0
0
88,245,536
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000088,245,536001,274,8101,454,40100000000
> Total Liabilities 
93,186,384
89,433,699
91,763,778
86,394,198
84,196,374
79,605,892
78,022,620
83,442,286
88,503,624
93,807,705
77,303,417
84,694,521
85,160,910
83,900,465
82,293,871
73,668,890
79,459,803
81,810,031
80,478,765
89,209,751
99,748,927
101,963,171
103,982,338
113,212,626
117,586,672
122,309,534
132,652,144
136,968,480
136,968,480132,652,144122,309,534117,586,672113,212,626103,982,338101,963,17199,748,92789,209,75180,478,76581,810,03179,459,80373,668,89082,293,87183,900,46585,160,91084,694,52177,303,41793,807,70588,503,62483,442,28678,022,62079,605,89284,196,37486,394,19891,763,77889,433,69993,186,384
   > Total Current Liabilities 
42,918,060
39,282,050
41,032,051
35,560,366
37,468,910
34,287,063
31,867,325
36,673,590
40,893,357
45,533,934
28,788,228
39,787,136
40,183,036
39,043,070
36,712,775
30,140,067
35,512,863
36,115,240
33,691,626
48,329,180
59,187,212
50,762,036
53,260,127
49,631,666
39,777,854
59,854,944
71,390,638
75,055,135
75,055,13571,390,63859,854,94439,777,85449,631,66653,260,12750,762,03659,187,21248,329,18033,691,62636,115,24035,512,86330,140,06736,712,77539,043,07040,183,03639,787,13628,788,22845,533,93440,893,35736,673,59031,867,32534,287,06337,468,91035,560,36641,032,05139,282,05042,918,060
       Short-term Debt 
22,575,100
22,000,000
21,000,000
2,166,667
2,166,480
2,166,480
2,166,480
2,166,480
8,366,480
10,666,480
2,166,480
7,866,480
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000007,866,4802,166,48010,666,4808,366,4802,166,4802,166,4802,166,4802,166,4802,166,66721,000,00022,000,00022,575,100
       Short Long Term Debt 
22,575,100
22,000,000
21,000,000
2,166,667
2,166,480
2,166,480
2,166,480
2,166,480
8,366,480
10,666,480
2,166,480
7,866,480
8,266,480
9,166,480
7,166,480
2,666,480
6,166,480
6,666,480
3,166,480
9,666,480
26,766,477
13,666,480
18,917,600
11,125,980
3,750,000
6,000,000
16,500,000
25,000,000
25,000,00016,500,0006,000,0003,750,00011,125,98018,917,60013,666,48026,766,4779,666,4803,166,4806,666,4806,166,4802,666,4807,166,4809,166,4808,266,4807,866,4802,166,48010,666,4808,366,4802,166,4802,166,4802,166,4802,166,4802,166,66721,000,00022,000,00022,575,100
       Accounts payable 
16,978,842
14,419,788
14,152,565
13,901,600
12,734,483
14,501,276
13,293,917
15,022,805
16,605,307
16,724,280
11,384,004
13,643,127
17,736,378
15,369,059
13,431,547
10,082,301
15,209,367
13,866,345
12,706,002
15,579,064
15,521,587
22,089,651
19,669,278
20,699,536
21,870,390
25,442,598
25,925,609
19,407,907
19,407,90725,925,60925,442,59821,870,39020,699,53619,669,27822,089,65115,521,58715,579,06412,706,00213,866,34515,209,36710,082,30113,431,54715,369,05917,736,37813,643,12711,384,00416,724,28016,605,30715,022,80513,293,91714,501,27612,734,48313,901,60014,152,56514,419,78816,978,842
       Other Current Liabilities 
12,067,088
11,022,309
14,029,218
14,405,969
12,778,903
13,687,029
10,125,242
9,664,891
781,930
683,413
2,480,794
1,221,497
2,295,790
1,236,919
1,229,974
1,272,062
1,284,419
1,390,389
1,669,167
1,979,720
2,012,261
2,156,403
2,010,701
1,719,811
1,736,772
2,608,644
2,594,834
1,340,315
1,340,3152,594,8342,608,6441,736,7721,719,8112,010,7012,156,4032,012,2611,979,7201,669,1671,390,3891,284,4191,272,0621,229,9741,236,9192,295,7901,221,4972,480,794683,413781,9309,664,89110,125,24213,687,02912,778,90314,405,96914,029,21811,022,30912,067,088
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
47,610,266
48,273,770
48,515,189
44,907,386
44,977,874
44,857,395
45,581,095
43,528,824
43,946,940
45,694,791
46,787,140
40,880,570
40,561,715
51,201,135
50,722,211
63,580,961
77,808,818
62,454,590
61,261,506
61,913,345
61,913,34561,261,50662,454,59077,808,81863,580,96150,722,21151,201,13540,561,71540,880,57046,787,14045,694,79143,946,94043,528,82445,581,09544,857,39544,977,87444,907,38648,515,18948,273,77047,610,26600000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
1,480,778
1,280,088
1,029,545
803,473
876,609
1,328,655
1,107,398
823,927
1,135,454
2,215,639
1,966,105
1,766,846
1,474,515
1,279,497
1,010,316
695,086
966,189
665,842
1,678,866
1,504,239
1,504,2391,678,866665,842966,189695,0861,010,3161,279,4971,474,5151,766,8461,966,1052,215,6391,135,454823,9271,107,3981,328,655876,609803,4731,029,5451,280,0881,480,77800000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
1,109,224
1,098,550
888,270
1,318,503
1,007,234
1,044,687
1,093,204
1,142,185
1,201,931
1,372,782
1,969,128
2,428,372
2,677,928
2,806,687
2,766,406
2,575,063
2,363,777
2,172,118
2,194,124
1,833,729
1,833,7292,194,1242,172,1182,363,7772,575,0632,766,4062,806,6872,677,9282,428,3721,969,1281,372,7821,201,9311,142,1851,093,2041,044,6871,007,2341,318,503888,2701,098,5501,109,22400000000
> Total Stockholder Equity
106,168,001
117,980,291
118,911,855
119,577,620
119,649,715
119,991,128
117,836,672
115,109,695
113,354,789
116,809,873
119,668,887
115,751,148
117,607,806
118,380,127
118,096,343
114,431,839
112,661,194
108,371,772
104,561,402
104,885,462
103,419,306
101,997,908
99,890,121
89,870,191
89,802,010
88,176,016
87,332,635
89,632,344
89,632,34487,332,63588,176,01689,802,01089,870,19199,890,121101,997,908103,419,306104,885,462104,561,402108,371,772112,661,194114,431,839118,096,343118,380,127117,607,806115,751,148119,668,887116,809,873113,354,789115,109,695117,836,672119,991,128119,649,715119,577,620118,911,855117,980,291106,168,001
   Common Stock
88,810,000
91,446,366
91,446,366
91,446,366
91,446,366
91,446,366
91,446,366
91,446,366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000091,446,36691,446,36691,446,36691,446,36691,446,36691,446,36691,446,36688,810,000
   Retained Earnings 
14,388,088
15,960,406
16,891,970
17,721,254
17,629,830
17,971,244
15,816,787
13,089,810
11,334,904
14,789,988
17,649,003
13,731,263
15,587,921
16,360,242
16,076,458
12,411,954
10,641,309
6,351,887
2,541,518
2,865,578
1,399,421
-21,977
-2,129,764
-12,149,694
-12,217,875
-13,843,869
-14,687,250
-17,820,613
-17,820,613-14,687,250-13,843,869-12,217,875-12,149,694-2,129,764-21,9771,399,4212,865,5782,541,5186,351,88710,641,30912,411,95416,076,45816,360,24215,587,92113,731,26317,649,00314,789,98811,334,90413,089,81015,816,78717,971,24417,629,83017,721,25416,891,97015,960,40614,388,088
   Capital Surplus 0000000000000000000000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
163,518
-1
163,518
163,517
163,518
163,518
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000163,518163,518163,517163,518-1163,51800



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue234,902,460
Cost of Revenue-162,781,733
Gross Profit72,120,72772,120,727
 
Operating Income (+$)
Gross Profit72,120,727
Operating Expense-231,785,066
Operating Income3,117,394-159,664,339
 
Operating Expense (+$)
Research Development11,909,304
Selling General Administrative24,048,519
Selling And Marketing Expenses0
Operating Expense231,785,06635,957,823
 
Net Interest Income (+$)
Interest Income11,324
Interest Expense-2,875,009
Other Finance Cost-0
Net Interest Income-2,863,685
 
Pretax Income (+$)
Operating Income3,117,394
Net Interest Income-2,863,685
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-3,917,8963,117,394
EBIT - interestExpense = -2,875,009
-3,875,543
-1,000,534
Interest Expense2,875,009
Earnings Before Interest and Taxes (EBIT)0-1,042,887
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-3,917,896
Tax Provision--42,353
Net Income From Continuing Ops-3,875,543-3,875,543
Net Income-3,875,543
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net02,863,685
 

Technical Analysis of Yungjin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Yungjin. The general trend of Yungjin is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Yungjin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Yungjin Pharm Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2,100 < 2,265 < 2,290.

The bearish price targets are: 2,005 > 2,005 > 2,005.

Tweet this
Yungjin Pharm Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Yungjin Pharm Co Ltd. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Yungjin Pharm Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Yungjin Pharm Co Ltd. The current macd is -3.29826939.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Yungjin price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Yungjin. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Yungjin price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Yungjin Pharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartYungjin Pharm Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Yungjin Pharm Co Ltd. The current adx is 29.09.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Yungjin shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Yungjin Pharm Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Yungjin Pharm Co Ltd. The current sar is 2,000.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Yungjin Pharm Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Yungjin Pharm Co Ltd. The current rsi is 57.20. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Yungjin Pharm Co Ltd Daily Relative Strength Index (RSI) ChartYungjin Pharm Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Yungjin Pharm Co Ltd. The current phase is Overbought in neutral market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Yungjin price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Yungjin Pharm Co Ltd Daily Stochastic Oscillator ChartYungjin Pharm Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Yungjin Pharm Co Ltd. The current cci is 38.51.

Yungjin Pharm Co Ltd Daily Commodity Channel Index (CCI) ChartYungjin Pharm Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Yungjin Pharm Co Ltd. The current cmo is 25.54.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Yungjin Pharm Co Ltd Daily Chande Momentum Oscillator (CMO) ChartYungjin Pharm Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Yungjin Pharm Co Ltd. The current willr is -9.09090909.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Yungjin Pharm Co Ltd Daily Williams %R ChartYungjin Pharm Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Yungjin Pharm Co Ltd.

Yungjin Pharm Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Yungjin Pharm Co Ltd. The current atr is 52.22.

Yungjin Pharm Co Ltd Daily Average True Range (ATR) ChartYungjin Pharm Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Yungjin Pharm Co Ltd. The current obv is 118,803,534.

Yungjin Pharm Co Ltd Daily On-Balance Volume (OBV) ChartYungjin Pharm Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Yungjin Pharm Co Ltd. The current mfi is 44.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Yungjin Pharm Co Ltd Daily Money Flow Index (MFI) ChartYungjin Pharm Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Yungjin Pharm Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Yungjin Pharm Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Yungjin Pharm Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.195
Ma 20Greater thanMa 502,064.250
Ma 50Greater thanMa 1002,060.400
Ma 100Greater thanMa 2002,063.550
OpenGreater thanClose2,060.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Yungjin with someone you think should read this too:
  • Are you bullish or bearish on Yungjin? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Yungjin? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Yungjin Pharm Co Ltd

I send you an email if I find something interesting about Yungjin Pharm Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Yungjin Pharm Co Ltd.

Receive notifications about Yungjin Pharm Co Ltd in your mailbox!